Gail Model — Breast Cancer Risk (BCRAT)

Why use it

The primary clinical tool for identifying women at elevated breast cancer risk who may benefit from chemoprevention (tamoxifen, raloxifene, aromatase inhibitors — FDA-approved for 5-year risk ≥ 1.66%) or enhanced screening (supplemental MRI). Enables evidence-based, personalized conversation about risk reduction strategies.

About

The Gail Model (Breast Cancer Risk Assessment Tool — BCRAT) is the most widely used and validated tool for estimating a woman's absolute risk of developing invasive breast cancer over the next 5 years and over her lifetime (to age 90). Developed by scientists at the NCI and NSABP, it incorporates epidemiologic risk factors from a prospective cohort. The model uses a relative risk logistic regression combined with age- and race-specific baseline absolute risk rates derived from SEER population data and competing mortality tables.

When to use

• Women aged 35 and older with no personal history of invasive breast cancer, DCIS, or LCIS
• Annual well-woman visits to assess breast cancer risk and guide screening decisions
• Evaluating chemoprevention eligibility (tamoxifen/raloxifene threshold: 5-year risk ≥ 1.66%)
• Patients with family history of breast cancer but no known high-penetrance mutation (BRCA1/2, PALB2, etc.)
• Population-based screening programs

Formula

Pearls & pitfalls

• CONTRAINDICATIONS: Do NOT use in women with personal history of breast cancer, DCIS, or LCIS.
• Do NOT use if patient has a known high-penetrance mutation (BRCA1/2, PALB2, PTEN, TP53, CDH1, STK11).
• The 1.66% threshold derives from the NSABP P-1 Breast Cancer Prevention Trial eligibility criterion — not a natural breakpoint in biology.
• Atypical hyperplasia on biopsy is the strongest individual risk factor in the model — nearly doubles relative risk.
• Gail UNDERESTIMATES risk in hereditary breast cancer syndromes. Use BOADICEA/Tyrer-Cuzick for >2 affected relatives.
• The model captures only first-degree relatives on the maternal side — paternal history is NOT incorporated.
• Validated primarily in White/Caucasian women; separate race-specific versions exist (African American, Asian American, Hispanic).
• A 5-year risk of 1.66% is roughly equivalent to average risk at age 60.

Next steps

If 5-year risk ≥ 1.66%: discuss chemoprevention (tamoxifen for premenopausal, raloxifene or AIs for postmenopausal) and consider earlier/supplemental MRI screening. If strong family history or suspected hereditary syndrome not captured by Gail: use BOADICEA or Tyrer-Cuzick and refer to genetics. Always discuss lifestyle modifications (weight, alcohol, hormone use).

Evidence

Originally developed from 2,852 breast cancer cases in the Breast Cancer Detection Demonstration Project (BCDDP) by Gail et al. (JNCI, 1989). Validated in the BCPT (P-1) trial (NSABP, 1998) and STAR trial. Baseline rates updated with SEER data. Endorsed by USPSTF, NCCN (v3.2023), ACOG, and NCI. The NCI BCRAT (bcrisktool.cancer.gov) uses the official implementation with competing mortality adjustment.

References

1. Gail MH et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-86. — link
2. Costantino JP et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541-8. — link
3. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst. 2008;100(14):1037-41. — link